Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -3 of 3 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:

Last Modified: 6/14/2006 First Published: 3/13/2006


1.		Phase I/II Study of Carboplatin, Melphalan, and Etoposide Phosphate in Combination With Blood-Brain Barrier Disruption With Mannitol and Delayed Sodium Thiosulfate in Patients With Anaplastic Oligodendroglioma or Oligoastrocytoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 to 75				NCI				OHSU-8507 OHSU-2868, OHSU-SOL-04058-L, NCT00303849

Last Modified: 1/8/2009 First Published: 2/10/2006


2.		Phase I/II Study of Rituximab in Combination With Blood-Brain Barrier Disruption With Mannitol, Combination Chemotherapy Comprising Methotrexate and Carboplatin, and Delayed Sodium Thiosulfate in Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 to 75				NCI				OHSU-1012 OHSU-SOL-05025-L, NCT00293475

Last Modified: 8/16/2008 First Published: 11/4/2005


3.		Phase I Study of Intra-Arterial Melphalan and Mannitol in Patients With Central Nervous System Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 months and over				NCI				OHSU-1299 OHSU-ONC-98018-L, OHSU-4834, NCT00253721

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute